Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

A proposed rule by the agency would create a streamlined registration pathway for advanced distributed manufacturing establishments. 

The FDA Moves to Modernize Drug Manufacturing Registration

Jamie Evans is manager of analytical method development and validation at Lonza Capsugel.

Joe Cobb, CPIP is manager of formulations at Lonza Capsugel.

PharmTech spoke with Jamie Evans, manager of analytical method development and validation, and Joe Cobb, CPIP, manager of formulations, both with Lonza Capsugel, about best practices for pharmaceutical technology transfer.

Structuring Tech Transfer for Optimized Collaboration

Tim Stroud is Solutions Consultant Team Leader at Cenevo. He is an experienced life sciences professional with more than 20 years in the pharmaceutical drug discovery industry. Prior to joining Cenevo, he worked as a scientist and lab automation specialist in the pharmaceutical industry at Pfizer and AstraZeneca. He leads Cenevo's team of solutions consultants, who deliver expert support to the sales teams in providing laboratory automation and software solutions to our clients in the academic, biotech, pharma, hospital, and agriscience sectors. www.cenevo.com

To drive long-term success, CROs need to strengthen their focus on efficiency, automation, data integrity, and compliance to generate higher ROI for clients.

It’s Time to Build a More Scalable, Connected CRO

Angela Strzelecki, PhD, is senior vice president of the Roquette Group and CEO of Roquette’s Health & Pharma Solutions Business Unit

Advances in personalized medicine, biopharma, and digital technologies are unlocking treatments for complex and rare conditions.

The Next Generation of Medicine: Personalized, Preventive, and Powered by Technology

The outsourcing company is adding commercial-scale capabilities to manufacture HPAPI and ADC payload-linkers.

Lonza Increases HPAPI Production at Visp Facility

David O’Connell is director of Scientific and Technical Affairs for PCI Pharma Services.

Treatment pipelines for rare diseases have never been more promising. Optimizing their impact will require integrated, precision-first CDMO support systems.

Optimizing Impact for Rare Diseases

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid US reshoring and oral dose innovation trends.

Tom Sellig on CDMO Innovation and US Manufacturing Growth

Erez Israeli is chief executive officer of Dr. Reddy's Laboratories.

Erez Israeli, chief executive officer of Dr. Reddy's Laboratories, provides insight on the company’s generic version of semaglutide, which entered the Canadian market in May 2026.

Generic GLP-1s Enter Canadian Market

Dr. Christine Allen is co-founder and CEO of Intrepid Labs. Dr. Allen is an internationally recognized expert in drug formulation and development, with over 200 peer-reviewed publications. She is a Professor at the University of Toronto and a Fellow of both the American Institute for Medical and Biological Engineering and the Canadian Academy of Health Sciences. She has held numerous leadership roles across academia and industry, including President of the Controlled Release Society and Editor-in-Chief of the 

Dr. Andrew Lewis is Chief Scientific Officer of Quotient Sciences. As the leader of Quotient Sciences' scientific teams and drug development consultants, Dr. Lewis is responsible for driving efficiency and innovation within our scientific organization, both to better serve our customers and drive growth for the Company.

Andy has over 25 years of experience in the pharmaceutical and drug delivery industry and is a member of the Academy of Pharmaceutical Scientists of Great Britain. Additionally, Andy has served on the board of directors of the Controlled Release Society, most recently as secretary.

Prior to joining Quotient Sciences, Andy was Director of Novel Drug Delivery Technologies at Ipsen. He holds a Ph.D. in Tissue Engineering and a Bachelor of Pharmacy, both from the University of Nottingham.

Dr. Christine Allen, Co-Founder and CEO of Intrepid Labs, and Dr. Andrew Lewis, Chief Scientific Officer of Quotient Sciences, explain how AI can be used in drug development to shorten development timelines. 

Pharma Fundamentals: Utilizing Artificial Intelligence in Drug Development

Ranjit Deshmukh is Principal at BiologixCMC.

Videos

Ranjit Deshmukh, Principal, BiologixCMC, discusses how contract manufacturers can optimize their processes and plan for the future by optimizing facility design. 